Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rapid infusion of VPRIV in type 1 Gaucher disease
NCT04120506Phase 4Completed
- Sponsor
- Shaare Zedek Medical Center
- Start
- Jan 2016
- Primary completion
- Jan 2017
- Modality
- Replacement Enzymes
01
Overview
Phase 4, open-label, single-arm trial of velaglucerase alfa in Gaucher disease type 1 (GD1), sponsored by Shaare Zedek Medical Center. Primary endpoints: Incidence of change from baseline in blood pressure at 9 months, Incidence of change from baseline in heart rate at 9 months and 1 more. Started Jan 2016; status: completed.
02
Drugs
velaglucerase alfa
03
Conditions
Gaucher disease type 1 (GD1)
Beyond the preview
Go deeper on NCT04120506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04120506.